immunotherapy – Medxy AI

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

By MedXY 07/31/2025

Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.

Clinical Updates Wellness & Lifestyle

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

By MedXY 07/31/2025

Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.

Clinical Updates Wellness & Lifestyle

Cockroach Immunotherapy Modulates Key T-Cell Responses Regardless of Allergen Extract Abundance

By MedXY 07/30/2025

A randomized trial finds that subcutaneous cockroach immunotherapy effectively downregulates dominant T-cell responses in pediatric asthma, independent of allergen abundance in the therapeutic extract.

Medical News

AI-Designed Proteins Revolutionize Personalized Cancer Treatment

By MedXY 07/25/2025

AI-powered protein design offers a fast, personalized approach to cancer treatment, enhancing immune response and minimizing side effects.